comprehensive -WSS

comprehensive

author：fashion 2025-08-11 07:58:49 - browse：86515

Is no one safe from the FTC? Has Pfizer bottomed out? And is biotech finally back?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we delve into the fallout over the FTC’s move to block what looked like a humdrum biotech deal between Sanofi and Maze Therapeutics, a surprising twist that leaves an unanswered question. We also discuss the latest news in the life sciences, including Pfizer’s downbeat future, Vertex Pharmaceuticals’ next big thing, and a newly minted biotech VC with a very famous name.

For more on what we cover, here’s the FTC news; here’s more from Maze Therapeutics; here’s the Pfizer news; here’s the latest on Vertex; here’s the story behind its pain drug; here’s the Reed Jobs profile; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Drug repurposing or repositioning? The language matters
Next article： Assistant physicians can help address the primary care shortage

entertainment

WSS

Roche's accidental data boosts hopes for anti

FDA advisory panel to debate high blood pressure devices

David Liu startup to focus on CRISPR delivery

Meadows told special counsel he could not recall Trump ever declassifying Mar

Vivek Ramaswamy made waves in the debate, much as in biotech

Wegovy improves function in certain heart failure patients

focus

comprehensive

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Republicans love RFK Jr. What's that tell us about health in 2024?

How to save PrEP access — and even expand it

The struggle to figure out which patients 'deserve' Wegovy

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA weighs limits of animal data in assessing artificial wombs

Supreme Court strikes down use of affirmative action

Fed up with FDA, ALS advocates consider a take

23andMe had bad news about my health. I wish a person had delivered it

Covid’s new normal has set in amid another rise in cases

focus

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

PBMs drew scrutiny in House hearing — and so did pharma

Assistant physicians can help address the primary care shortage

Former Pear Therapeutics executives start new VC firm

As obesity drug market grows, telehealth companies court payers

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

entertainment

leisure time

Wikipedia

Wikipedia